Statistical results for metaphase and interphase analyses
Study (figure no.), cytogenic result . | Cell stage . | Patients, n . | Deaths, n . | Median survival, mo . | 95% CI, mo . |
|---|---|---|---|---|---|
| Percentage of abnormal nuclei versus survival (1B ) | |||||
| Greater than 50% abnormal nuclei | Interphase | 20 | 18 | 6.7 | 2.4-18.9 |
| Less than 50% abnormal nuclei | Interphase | 134 | 83 | 45.0 | 36.7-53.1 |
| Normal metaphases versus abnormal metaphases (1C ) | |||||
| Abnormal | Metaphase | 61 | 48 | 19.6 | 14.2-37.8 |
| Normal | Metaphase | 93 | 50 | 46.8 | 42.1-64.2 |
| 13q anomalies in interphase or metaphase (1D ) | |||||
| 13q- | Metaphase | 30 | 29 | 12.7 | 5.9-23.9 |
| All tests normal | Interphase and metaphase | 21 | 10 | 45.0 | 37.6-NA |
| 13q- | Interphase | 38 | 26 | 46.8 | 24.1-64.2 |
| Abnormal without 13q- | Metaphase | 31 | 20 | 53.1 | 17.2-NA |
| Normal metaphase and abnormal interphase no 13q- | Interphase and metaphase | 34 | 16 | 55.3 | 36.7-NA |
| Hierarchy of chromosome anomalies and survival*(1E ) | |||||
| t(4;14), t(14;16), 17p-, or 13q- | Metaphase | 33 | 30 | 13.9 | 5.9-23.9 |
| t(11;14) without t(4;14), t(14;16), 17p-, or 13q- | Metaphase | 6 | 5 | 31.0 | 17.0-NA |
| Normal | Metaphase | 93 | 52 | 46.7 | 42.1-64.2 |
| Remaining patients | Metaphase | 22 | 14 | 41.6 | 17.2-NA |
| Hierarchy of chromosome anomalies and survival*(1F ) | |||||
| t(4;14), t(14;16) | Interphase | 20 | 18 | 13.3 | 6.3-37.8 |
| 13q- or 17p- without t(4;14), t(14;16) | Interphase | 59 | 44 | 33.9 | 19.3-55.5 |
| Normal | Interphase | 21 | 10 | 45.0 | 37.6-NA |
| More than 2 CCND1 and other | Interphase | 39 | 21 | 53.1 | 30.1-NA |
| t(11;14) without t(4;14), t(14;16), 17p-, or 13q- | Interphase | 15 | 8 | 55.3 | 31.0-NA |
Study (figure no.), cytogenic result . | Cell stage . | Patients, n . | Deaths, n . | Median survival, mo . | 95% CI, mo . |
|---|---|---|---|---|---|
| Percentage of abnormal nuclei versus survival (1B ) | |||||
| Greater than 50% abnormal nuclei | Interphase | 20 | 18 | 6.7 | 2.4-18.9 |
| Less than 50% abnormal nuclei | Interphase | 134 | 83 | 45.0 | 36.7-53.1 |
| Normal metaphases versus abnormal metaphases (1C ) | |||||
| Abnormal | Metaphase | 61 | 48 | 19.6 | 14.2-37.8 |
| Normal | Metaphase | 93 | 50 | 46.8 | 42.1-64.2 |
| 13q anomalies in interphase or metaphase (1D ) | |||||
| 13q- | Metaphase | 30 | 29 | 12.7 | 5.9-23.9 |
| All tests normal | Interphase and metaphase | 21 | 10 | 45.0 | 37.6-NA |
| 13q- | Interphase | 38 | 26 | 46.8 | 24.1-64.2 |
| Abnormal without 13q- | Metaphase | 31 | 20 | 53.1 | 17.2-NA |
| Normal metaphase and abnormal interphase no 13q- | Interphase and metaphase | 34 | 16 | 55.3 | 36.7-NA |
| Hierarchy of chromosome anomalies and survival*(1E ) | |||||
| t(4;14), t(14;16), 17p-, or 13q- | Metaphase | 33 | 30 | 13.9 | 5.9-23.9 |
| t(11;14) without t(4;14), t(14;16), 17p-, or 13q- | Metaphase | 6 | 5 | 31.0 | 17.0-NA |
| Normal | Metaphase | 93 | 52 | 46.7 | 42.1-64.2 |
| Remaining patients | Metaphase | 22 | 14 | 41.6 | 17.2-NA |
| Hierarchy of chromosome anomalies and survival*(1F ) | |||||
| t(4;14), t(14;16) | Interphase | 20 | 18 | 13.3 | 6.3-37.8 |
| 13q- or 17p- without t(4;14), t(14;16) | Interphase | 59 | 44 | 33.9 | 19.3-55.5 |
| Normal | Interphase | 21 | 10 | 45.0 | 37.6-NA |
| More than 2 CCND1 and other | Interphase | 39 | 21 | 53.1 | 30.1-NA |
| t(11;14) without t(4;14), t(14;16), 17p-, or 13q- | Interphase | 15 | 8 | 55.3 | 31.0-NA |
CI indicates confidence interval; NA, not achieved.
Hierarchic grouping of patients by their chromosomal anomalies was based on hazard ratios from univariable and multivariable survival models